Amifampridine tablets for the treatment of Lambert-Eaton myasthenic syndrome.

Amifampridine tablets for the treatment of Lambert-Eaton myasthenic syndrome. Expert Rev Clin Pharmacol. 2019 Oct 22;:1-6 Authors: Mantegazza R Abstract Introduction: Lambert-Eaton myasthenic syndrome is an autoimmune disease of the neuromuscular junction characterized by a presynaptic defect of neuromuscular transmission resulting in muscle weakness and fatigability. Diagnostic features are specific neurophysiological alterations and autoantibody detection. The present review is focused on the use of Amifampridine Phosphate to treat LEMS patients. Areas covered: Medline search from 1990 to 2019 was examined using the free subject terms: Lambert-Eaton myasthenic syndrome, LEMS, Amifampridine, 3,4-diaminopyridine, which were then combined with Treatment, Therapy, Clinical Trial, Controlled Clinical Trial, Randomized Clinical Trial and Cochrane Review. The author has done a supervised analysis of the retrieved articles and focused on those subjectively evaluated as most relevant. Expert commentary: Data from randomized clinical trials and case series have demonstrated that Lambert-Eaton myasthenic syndrome symptoms were successfully treated by Amifampridine Phosphate. Hence, the drug represents a substantial step forward in the symptomatic treatment of the disease due to its efficacy, safety and reliable GMP formulation. As Amifampridine Phosphate works by enhancing the release of acetylcholine at the neuromuscular junction by blocking K+ efflux at the pre...
Source: Pharmacological Reviews - Category: Drugs & Pharmacology Authors: Tags: Expert Rev Clin Pharmacol Source Type: research

Related Links:

Myasthenia gravis (MG) is a rare autoimmune disease mainly mediated by autoantibodies against the acetylcholine receptor (AChR) at the neuromuscular junction. The thymus is the effector organ, and its removal ...
Source: Journal of Neuroinflammation - Category: Neurology Authors: Tags: Research Source Type: research
Conclusions: Our findings suggest a role of the thymus in the maintenance of humoral thyroid autoimmunity.Eur Thyroid J
Source: European Thyroid Journal - Category: Endocrinology Source Type: research
ConclusionsLack of availability of sound scientific knowledge inevitably lead unreliable news to spread over the population, preventing people to disentangle them form reliable information. Even if additional studies are needed to replicate and strengthen our results, these findings represent initial evidence to derive recommendations based on actual data for subjects with autoimmune diseases.
Source: Autoimmunity Highlights - Category: Allergy & Immunology Source Type: research
Conclusion: Patients with MuSK-MG in Northeast China have a modestly later onset age and a proportion of patients may have a mild form of the disease with delayed disease progression. We confirmed the existence of a rare ocular MuSK-MG phenotype, a high proportion of coexisting with other autoimmune diseases, and a good response to steroids combined with tacrolimus for our MuSK-MG series.
Source: Frontiers in Neurology - Category: Neurology Source Type: research
Myasthenia Gravis (MG), an autoimmune neurological disease, is more frequently found amongst adults than amongst children. Our research provides data on the clinical symptoms, forms of MG, effective treatment, the presence of thymoma and the effect of thymectomy in children with MG in Israel. The database of a tertiary pediatric medical center was retrospectively reviewed for patients under 18 years of age diagnosed between the years 2000-2020 with either ocular or systemic acquired myasthenia gravis.
Source: Neuromuscular Disorders - Category: Neurology Authors: Source Type: research
AbstractMyasthenia gravis (MG) is an autoimmune disease characterised by the presence of acetylcholine receptor antibodies and by blocking the transmission of the signal in the neuromuscular junction causing muscle weakness. It can be associated with several autoimmune diseases and certain drugs, between them Etanercept an anti-tumour necrosis factor (TNF) agent. A 42-year-old woman with rheumatoid arthritis (RA) refractory to methotrexate, was treated with adalimumab (ADA), a human monoclonal antibody against the TNF, in a dosage scheme of 40  mg every 14 days subcutaneously. The patient responded well to ADA th...
Source: Rheumatology International - Category: Rheumatology Source Type: research
Myasthenia gravis (MG), an autoimmune neuromuscular disorder, may be a risk factor for severe COVID-19. We conducted an observational retrospective study with 15 consecutive adult MG patients admitted with COVID-19 at four hospitals in São Paulo, Brazil. Most patients with MG hospitalized for COVID-19 had severe courses of the disease: 87% were admitted in the intensive care unit, 73% needed mechanical ventilation, and 30% died. Immunoglobulin use and the plasma exchange procedure were safe. Immunosuppressive therapy seems to be associated with better outcomes, as it might play a protective role.
Source: Frontiers in Neurology - Category: Neurology Source Type: research
AbstractMyasthenia gravis (MG) is an autoimmune, neuromuscular disorder that produces disabling weakness through a compromise of neuromuscular transmission. The disease fulfills strict criteria of an antibody-mediated disease. Close to 90% of patients have antibodies directed towards the nicotinic acetylcholine receptor (AChR) on the post-synaptic surface of skeletal muscle and another 5% to the muscle-specific kinase, which is involved in concentrating the AChR to the muscle surface of the neuromuscular junction. Conventional treatments of intravenous immunoglobulin and plasma exchange reduce autoantibody levels to produc...
Source: BioDrugs - Category: Drugs & Pharmacology Source Type: research
In conclusion, different subtypes of MG harbored differential gut microbiota, which generated discriminative fecal metabolism.
Source: Frontiers in Microbiology - Category: Microbiology Source Type: research
Conclusion: The coexistence of SS with MG is quite rare. The onset of MG may occur before or after the diagnosis of SS. Co-morbidity with MG does not seem to adversely affect the course of SS. Thus, controlling the progress of MG is the critical aspect of treatment.
Source: Frontiers in Neurology - Category: Neurology Source Type: research
More News: Autoimmune Disease | Brain | Clinical Trials | Drugs & Pharmacology | Myasthenia Gravis | Neurology